DeepMed Research

Chemomab Ltd.

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.chemomab.com

Clinical Trials

Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

Phase 2

Suspended

Conditions: Systemic Sclerosis

Interventions: Drug: 10 mg/kg CM-101
Drug: Placebo

First Posted Date: 2024-01-18

Last Posted Date: 2024-01-18

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 45

Registration Number: NCT06210945

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Phase 1

Completed

Conditions: Nonalcoholic Fatty Liver Disease

Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Drug: Placebo - Study Part One
Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Drug: Placebo - Study Part Two

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 16

Registration Number: NCT06044467

Locations: 🇮🇱
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)
Primary Sclerosing Cholangitis (PSC)
Systemic Sclerosis (SSc)

Interventions: Drug: CM-101
Drug: Placebo

First Posted Date: 2023-09-14

Last Posted Date: 2023-09-14

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 8

Registration Number: NCT06037577

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Anti-human CCL24 monoclonal antibody (CM-101)

First Posted Date: 2023-09-06

Last Posted Date: 2023-09-11

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 32

Registration Number: NCT06025851

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

CM-101 in NASH Patients - The SPLASH Study

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Biological: 5 mg/kg CM-101
Other: Placebo

First Posted Date: 2023-04-21

Last Posted Date: 2023-04-21

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 23

Registration Number: NCT05824156

Locations: 🇮🇱
Carmel Medical Center - site 207, Haifa, Israel
🇮🇱
Rambam Medical Center - site 202, Haifa, Israel
🇮🇱
Soroka Medical Center - site 203, Be'er Sheva, Israel

and more 6 locations

CM-101 in PSC Patients -The SPRING Study

Phase 2

Active, not recruiting

Conditions: Primary Sclerosing Cholangitis

Interventions: Other: Placebo
Biological: Anti-human CCL24 monoclonal antibody (CM-101)

First Posted Date: 2020-10-22

Last Posted Date: 2024-01-09

Lead Sponsor: ChemomAb Ltd.

Target Recruit Count: 68

Registration Number: NCT04595825

Locations: 🇺🇸
Massachusetts General Hospital - site P95, Boston, Massachusetts, United States
🇺🇸
Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81, Boston, Massachusetts, United States
🇮🇱
Assuta Medical Center - site P31, Tel Aviv, Israel

and more 30 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy